The Latest Breaking News from FDA

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

As faces chase agelessness, cosmetic procedures are surging – and the taboo against commenting on women’s appearances is beginning to dissolve

Altria Group, Inc. (MO) has emerged as a dominant market player, thanks to its diverse tobacco portfolio that’s leading the shift from traditional smoking. With strong financial performance and over 50 years of consistent dividend payouts, could this stable, high-performing stock be a worthy addition to your portfolio? Read on….

We recognize some of the most staggering, game-changing, life-improving developments of the year.

Doctors weigh in on the popular supplement during cold season

“Daniel was probably the best boss I ever had,” said one of his former deputies, “but also one of the most challenging.”

The FDA has issued its strongest safety alert, a boxed warning, on a menopausal drug linked to severe liver injury.

With an average of over 1,284 drugs recalled annually, the pharmaceutical industry demands vigilance. Quality control issues, ranging from incorrect labeling to contamination, can result in costly recalls, regulatory fines, and reputational damage.

A third-party lab caught OpenAI's o1 model trying to deceive, while OpenAI's safety testing has been called into question.

The drug Librela was approved to control pain associated with osteoarthritis in dogs.

People worried they'll never get a scarce human transplant want to know when they might get a pig kidney instead